Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3
AssigneeOliX Pharmaceuticals, Inc.
InventorsDong-ki Lee, Sun Woo Hong, Isu Hong, Jihye Hwang
Life of this patent
Estimating the term…
Abstract
In certain aspects, provided herein are RNA complexes that inhibit Myeloid differentiation primary response gene 88 (MyD88) and/or Toll-like receptor 3 (TLR3) and are useful in the treatment of age-related macular degeneration (AMD). In certain aspects, provided herein are pharmaceutical compositions comprising such RNA complexes and methods of using such RNA complexes and pharmaceutical compositions.
Claims19
A method of treating age-related macular degeneration (AMD) in a subject, comprising administering to the subject an RNA duplex of an antisense strand of at least 19 nucleotides (nt) in length and a sense strand of 16 nt in length, wherein:
- the sequence of the antisense strand comprises SEQ ID NO:
- 54 or SEQ ID NO:
- 56;
- the sequence of the sense strand is SEQ ID NO:
- 53 or SEQ ID NO:
- 55;
- a cholesterol moiety is attached to the 3′ end of the sense strand;
- and
- the antisense strand and the sense strand form a complex in which the 5′ end of the antisense strand and the 3′ end of the sense strand form a blunt end.
Dependencies are inferred from the claim text.